Cited 31 time in
Enhancement of specialized metabolites using CRISPR/Cas gene editing technology in medicinal plants
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Das, Swati | - |
| dc.contributor.author | Kwon, Moonhyuk | - |
| dc.contributor.author | Kim, Jae-Yean | - |
| dc.date.accessioned | 2024-03-24T02:31:23Z | - |
| dc.date.available | 2024-03-24T02:31:23Z | - |
| dc.date.issued | 2024-02 | - |
| dc.identifier.issn | 1664-462X | - |
| dc.identifier.issn | 1664-462X | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/70040 | - |
| dc.description.abstract | Plants are the richest source of specialized metabolites. The specialized metabolites offer a variety of physiological benefits and many adaptive evolutionary advantages and frequently linked to plant defense mechanisms. Medicinal plants are a vital source of nutrition and active pharmaceutical agents. The production of valuable specialized metabolites and bioactive compounds has increased with the improvement of transgenic techniques like gene silencing and gene overexpression. These techniques are beneficial for decreasing production costs and increasing nutritional value. Utilizing biotechnological applications to enhance specialized metabolites in medicinal plants needs characterization and identification of genes within an elucidated pathway. The breakthrough and advancement of CRISPR/Cas-based gene editing in improving the production of specific metabolites in medicinal plants have gained significant importance in contemporary times. This article imparts a comprehensive recapitulation of the latest advancements made in the implementation of CRISPR-gene editing techniques for the purpose of augmenting specific metabolites in medicinal plants. We also provide further insights and perspectives for improving metabolic engineering scenarios in medicinal plants. Copyright © 2024 Das, Kwon and Kim. | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Frontiers Media S.A. | - |
| dc.title | Enhancement of specialized metabolites using CRISPR/Cas gene editing technology in medicinal plants | - |
| dc.type | Article | - |
| dc.publisher.location | 스위스 | - |
| dc.identifier.doi | 10.3389/fpls.2024.1279738 | - |
| dc.identifier.scopusid | 2-s2.0-85186597107 | - |
| dc.identifier.wosid | 001176069900001 | - |
| dc.identifier.bibliographicCitation | Frontiers in Plant Science, v.15 | - |
| dc.citation.title | Frontiers in Plant Science | - |
| dc.citation.volume | 15 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Plant Sciences | - |
| dc.relation.journalWebOfScienceCategory | Plant Sciences | - |
| dc.subject.keywordPlus | DOUBLE-STRAND BREAKS | - |
| dc.subject.keywordPlus | SECONDARY METABOLITES | - |
| dc.subject.keywordPlus | NICOTINE BIOSYNTHESIS | - |
| dc.subject.keywordPlus | OVER-EXPRESSION | - |
| dc.subject.keywordPlus | HAIRY ROOTS | - |
| dc.subject.keywordPlus | TRANSCRIPTIONAL REGULATION | - |
| dc.subject.keywordPlus | ARTEMISININ BIOSYNTHESIS | - |
| dc.subject.keywordPlus | HOMOLOGOUS RECOMBINATION | - |
| dc.subject.keywordPlus | MORPHINAN ALKALOIDS | - |
| dc.subject.keywordPlus | TAL EFFECTORS | - |
| dc.subject.keywordAuthor | CRISPR/Cas | - |
| dc.subject.keywordAuthor | gene editing | - |
| dc.subject.keywordAuthor | medicinal plants | - |
| dc.subject.keywordAuthor | metabolic engineering | - |
| dc.subject.keywordAuthor | specialized metabolites | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
